85/100 · Critical
High Serious Adverse Event Rate for Repaglinide
Last updated: 2026-05-12
REPAGLINIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS). Based on analysis of FDA adverse event reports, REPAGLINIDE has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for REPAGLINIDE.
Repaglinide has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately N/A adverse event reports for this medication.
Of classified reports, 92.5% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Over 92% of reports are serious, indicating significant health risks.
The majority of reports involve elderly patients, suggesting potential age-related side effects. A wide range of serious outcomes are reported, indicating diverse safety concerns.
Patients taking Repaglinide should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Repaglinide should be used with caution in elderly patients and those with cardiovascular conditions. Close monitoring for hypoglycemia is essential. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Repaglinide received a safety concern score of 85/100 (high concern). This is based on a 92.5% serious event ratio across 7,179 classified reports. The score accounts for N/A total adverse event reports and 0 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Male: 3,590, Female: 3,027, Unknown: 5. The most frequently reported age groups are age 73 (235 reports), age 75 (229 reports), age 77 (204 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 7,179 classified reports for REPAGLINIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Repaglinide should be used with caution in elderly patients and those with cardiovascular conditions. Close monitoring for hypoglycemia is essential.
If you are taking Repaglinide, here are important things to know. Patients should closely monitor their blood sugar levels and report any unusual symptoms to their healthcare provider. Elderly patients should be particularly vigilant due to the higher risk of serious adverse events. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Repaglinide for safety and has not issued any specific warnings or recalls.
The FDA has received approximately N/A adverse event reports associated with Repaglinide. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
Out of 7,179 classified reports, 6,639 (92.5%) were classified as serious and 540 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Repaglinide break down by patient sex as follows: Male: 3,590, Female: 3,027, Unknown: 5. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Repaglinide adverse events are: age 73: 235 reports, age 75: 229 reports, age 77: 204 reports, age 79: 197 reports, age 69: 196 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
You can report adverse events from Repaglinide to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Repaglinide has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Over 92% of reports are serious, indicating significant health risks.
Key safety signals identified in Repaglinide's adverse event data include: Cardiovascular events are frequently reported, including heart failure and arrhythmias.. Hypoglycemia is a common serious adverse event, especially in elderly patients.. Neurological issues, such as confusion and dizziness, are also reported.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Repaglinide should be used with caution in elderly patients and those with cardiovascular conditions. Close monitoring for hypoglycemia is essential. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Repaglinide.
Patients should closely monitor their blood sugar levels and report any unusual symptoms to their healthcare provider. Elderly patients should be particularly vigilant due to the higher risk of serious adverse events.
Repaglinide has N/A adverse event reports on file with the FDA. The majority of reports involve elderly patients, suggesting potential age-related side effects. The volume of reports for Repaglinide reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Repaglinide for safety and has not issued any specific warnings or recalls. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Drugs related to REPAGLINIDE based on therapeutic use, drug class, or shared indications: